Basal kinomic activity profiles.

<p>Unsupervised hierarchical clustering of basal (untreated) tyrosine kinomic profiles displaying log transformed slope-exposure for (<b>A</b>) all 144 peptides and (<b>B</b>) as change from sample mean and filtered for variance >1. Red in (A) indicates relative increased signal and in (B) indicates an increase from sample mean. Blue indicates the opposite. Blue arrowhead points to red line denoting dendrogram separation. (<b>C</b>) Western blotting of GAPDH and Actin is shown with sample concentration indicated for each patient.</p

<i>Ex vivo</i> drug response profile.

<p>Displays <i>ex</i><i>vivo</i> drug response profiles as (A) a heatmap of kinase activity (log signal values) change from untreated, clustered by row, of altered phosphopeptides per patient, per dose at 20 nM, 0.5 µM or 20 µM. (B) <i>Ex vivo</i> prewash kinetic peptide phosphorylation (y axis per cell) over time (x axis per cell) of selected peptides in the selected samples, in response to indicated drugs at 20 µM. Blue lines denote untreated, and green lines indicate treated phosphorylation curves.</p

Kinomic platform and Electromagnetic Navigation Bronchoscopy.

<p>(A) Overall experimental flow with a (B) Representative in-procedure display of ENB and a schematic of PamChip assay used to measure basal kinomic activity displayed as (C) raw array picture of the 144 phosphorylatable peptides and (D) phosphorylation changes with drug treatment displayed with illustration of comparative fluorescent detection below.</p

Patient characteristics and tumor evaluation.

<p>M-male; F-female; NSCLC-non small cell lung cancer; MD-PD-moderately differentiated to poorly differentiated; SBRT-stereotactic body radiotherapy.</p><p>Patient characteristics and tumor evaluation.</p

CONSORT diagram on patient enrollment.

<p>CONSORT diagram on patient enrollment.</p